^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Lung Adenocarcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report

    Published date:
    10/16/2020
    Excerpt:
    ...the patient was diagnosed with cT1N3M1 stage IVB lung adenocarcinoma. An EGFR exon 20 insertion, without any additional mutations, was identified….osimertinib was initiated to treat the EGFR exon 20 insertion-positive lung adenocarcinoma….and treatment with carboplatin as well as pemetrexed and bevacizumab was started, which the patient responded to.
    Secondary therapy:
    carboplatin + pemetrexed
    DOI:
    10.1097/MD.0000000000022628